Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -192.14% | -513.20% | -275.45% | -139.34% | -51.84% |
| Total Depreciation and Amortization | 15.24% | 261.07% | 884.85% | 751.52% | 9,839.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.52% | -123.41% | 325.32% | 330.69% | 324.76% |
| Change in Net Operating Assets | 87.03% | 39.24% | 752.83% | -309.64% | -637.10% |
| Cash from Operations | -155.15% | -292.68% | -173.22% | -129.38% | -65.64% |
| Capital Expenditure | 83.49% | 38.30% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 296.84% | -225.61% | 133.50% | -792.19% | -245.52% |
| Cash from Investing | 295.27% | -226.07% | 133.42% | -792.19% | -246.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.81% | -99.52% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | 43.44% | -99.47% | -- | -100.00% | -- |
| Foreign Exchange rate Adjustments | -291.30% | 555.02% | -6,608.00% | 88.30% | 9,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,153.30% | -246.79% | 117.90% | -125.61% | -31.55% |